GAL-101A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

Sponsor:

Galimedix Therapeutics Inc

Code:

NCT06659549

Conditions

Geographic Atrophy of the Macula

Eligibility Criteria

Sex: All

Age: 55+

Healthy Volunteers: Not accepted

Interventions

GAL-101

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-27. This information was provided to ClinicalTrials.gov by Galimedix Therapeutics Inc on 2026-08-20.